scFv-based biologics in diabetes: from therapeutic potential to clinical prospects - Takeaways - MDSpire

scFv-based biologics in diabetes: from therapeutic potential to clinical prospects

  • By

  • Shikun Ge

  • Luoxuan Wang

  • Yichen Huang

  • Huaizu Guo

  • Fuyao Wei

  • Pan Li

  • Siyuan Li

  • Qian Liu

  • Jin Xu

  • Yilei Xiao

  • Alberto Carlos Piress Dias

  • Lusha Ji

  • June 4, 2026

  • 0 min

Share

  • 1

    Single-chain variable fragments (scFv) are emerging as versatile biologics for precision diabetes management, addressing limitations of current therapies.

  • 2

    scFv offer enhanced tissue penetration and modular design, allowing for precise targeting of autoimmune and metabolic pathways in diabetes.

  • 3

    Avian-derived scFv can recognize conserved epitopes, overcoming immune tolerance and providing a unique advantage in therapeutic applications.

  • 4

    Engineering strategies like Fc fusion and PEGylation enhance the pharmacokinetics and efficacy of scFv-based biologics in diabetes treatment.

  • 5

    The integration of scFv with humanized Fc domains presents a promising strategy for next-generation diabetes therapies, bridging innovative design with clinical benefits.

Original Source(s)

scFv-based biologics in diabetes: from therapeutic potential to clinical prospects

  • by Shikun Ge, Luoxuan Wang, Yichen Huang, Huaizu Guo, Fuyao Wei, Pan Li, Siyuan Li, Qian Liu, Jin Xu, Yilei Xiao, Alberto Carlos Piress Dias, Lusha Ji

  • June 4, 2026

Related Content

A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues

Development and Internal Validation of a Multivariable Prediction Model for Postoperative Bleeding in Patients Undergoing Bariatric Surgery (The POD 1-DISCHARGE Calculator)

Correction to: “Determinants of Pancreatic Size and Fat Content in the UK Biobank: Influence of Race, Genetic Variants, and Risk Factors”

  • February 9, 2026